Welcome to our dedicated page for Alpha Tau Medical Ltd. SEC filings (Ticker: DRTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alpha Tau Medical Ltd. filings document the company's foreign-issuer current reports for Alpha DaRT clinical and regulatory updates. Recent Form 6-K reports furnish press releases and presentations covering studies in recurrent glioblastoma, recurrent cutaneous squamous cell carcinoma, pancreatic cancer, and head and neck cancer.
The filings describe trial enrollment, interim clinical data, safety observations, FDA device-related matters, conference presentations and company presentations furnished as exhibits. They also identify the company's Form 20-F reporting status and the treatment of furnished information under the Securities Exchange Act.
Alpha Tau Medical Ltd. (DRTS) announced completion of patient enrollment in IMPACT, a multicenter pilot study of its Alpha DaRT intratumoral alpha-radiation therapy combined with first-line chemotherapy for newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma. Enrollment expanded from 12 to 48 patients across 10 centers in the United States, Canada and Israel, reflecting strong interest from clinicians and patients.
The study evaluates feasibility, safety and preliminary efficacy of adding one-time Alpha DaRT treatment to standard mFOLFIRINOX or gemcitabine plus Abraxane chemotherapy. IMPACT’s primary endpoint is safety based on treatment-emergent adverse events, with secondary endpoints including overall and progression-free survival, pain control and surgical resection rate. Follow-up continues for up to six months per patient, with initial data targeted for early 2027 to help design a planned pivotal study within Alpha Tau’s broader global pancreatic cancer program.
Alpha Tau Medical Ltd. (DRTS) reported that Chief Financial Officer Levy Raphi exercised derivative securities to acquire 2,871 Ordinary Shares at $2.98 per share on August 21, 2026, and on the same day sold 2,871 Ordinary Shares at $15.0028 per share pursuant to a Rule 10b5-1 trading plan.
Alpha Tau Medical Ltd. (DRTS) has a notice from officer Raphael (Raphi) Aryeh Levy to sell 5,000 Ordinary Shares of the company under Rule 144. The broker is Oppenheimer & Co. Inc., and the shares are tied to a cash exercise of employee stock options scheduled for 08/21/2026.
The notice lists prior Rule 144 sales by Levy over the past three months, including multiple transactions in June, July, and August 2026 with aggregate dollar amounts disclosed for each trade. The sales are made pursuant to a Rule 10b5-1 trading plan adopted on 03/24/2026.
Alpha Tau Medical Ltd. Chief Financial Officer Raphi Levy reported two transactions in Ordinary Shares of Alpha Tau Medical Ltd. On 2026-08-11, he acquired 17,730 Ordinary Shares through an exercise or conversion of a derivative security at $2.98 per share, then on the same date sold 17,730 Ordinary Shares at $14.0032 per share. These trades were made pursuant to a Rule 10b5-1 trading plan. The filing does not state his total shareholdings after these transactions.
Alpha Tau Medical, a clinical-stage oncology company developing the Alpha DaRT localized alpha-radiation therapy, reported substantially higher losses for the six months ended June 30, 2026 while strengthening its balance sheet and advancing key clinical and commercial milestones.
Net loss rose to $68.8 million from $18.8 million, mainly due to a $42.2 million non‑cash increase in warrant fair value and higher research and development and general and administrative expenses. Operating loss increased to $27.1 million. Research and development spending grew 47% to $20.9 million as the company expanded trials and manufacturing capabilities.
Liquidity improved, with cash, cash equivalents, short‑term and restricted deposits totaling $104.8 million, which management believes funds operations for at least two years. A strategic collaboration with Tolmar granted Tolmar exclusive U.S. commercialization rights for prostate cancer, delivering a $15 million upfront payment and a $20 million equity investment at a premium; $18.9 million was recorded as deferred revenue and total initial transaction price for accounting purposes was $38.9 million. Alpha Tau also received shonin pre‑market approval in Japan for head & neck cancer, completed enrollment in its U.S. pivotal ReSTART cSCC trial, reported encouraging interim data in recurrent glioblastoma and pancreatic cancer programs, and continues to operate without product sales revenue.
Alpha Tau Medical Ltd. announced plans to become dual-listed by offering its ordinary shares for trading on the Tel Aviv Stock Exchange alongside Nasdaq. The company has requested TASE registration of 92,478,154 outstanding ordinary shares plus additional shares tied to existing and future equity incentives and employee purchase plans. Shares are expected to trade on TASE under the English symbol DRTS and Hebrew symbol דרטס. Alpha Tau continues to focus on development and potential commercialization of its Alpha DaRT alpha-radiation therapy for solid tumors.
Alpha Tau Medical Ltd. reported positive clinical data from a study combining its Alpha DaRT® alpha‑radiation therapy with pembrolizumab in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma.
Among nine evaluable patients, the combination produced a 100% objective response rate, with four complete and five partial responses, compared with historical pembrolizumab monotherapy benchmarks of about 19% objective response. Median overall survival was 18.2 months and median progression‑free survival was 5.4 months, which the company states compare favorably with historical pembrolizumab figures of 12.3 and 3.2 months, respectively.
No Alpha DaRT‑associated serious adverse events were observed; the only two Alpha DaRT‑associated events were Grade 1 (mild). The single‑arm study, designed to enroll up to 48 patients using a Simon two‑stage adaptive design, met its pre‑specified success criterion once more than six patients responded, and recruitment concluded after 11 patients.
Alpha Tau Medical Ltd. reports the first successful treatment of an immunocompromised patient with recurrent cutaneous squamous cell carcinoma (cSCC) using its Alpha DaRT therapy in the ADMIRE clinical study at Banner MD Anderson Cancer Center in Gilbert, Arizona.
ADMIRE is a prospective, multicenter, open-label, single-arm study evaluating intratumoral Alpha DaRT in immunocompromised patients with recurrent cSCC. It is designed to enroll up to 28 patients at up to 8 U.S. sites, each with a single lesion up to 7 cm. Eligible patients are immunocompromised due to causes such as solid organ transplantation, hematologic malignancy, or chronic immunosuppressive therapy. The primary endpoint is objective response rate per RECIST v1.1, with secondary endpoints including progression-free survival, overall survival, and local control assessed over twelve months.
Alpha Tau Medical Ltd. Chief Financial Officer Levy Raphi reported same-day share transactions involving the company’s Ordinary Shares. He exercised 2,270 shares at a price of $2.98 per share and sold 2,270 shares in an open-market sale at $14.0011 per share. Following these transactions, he directly held 90,180 Ordinary Shares.
Alpha Tau Medical Ltd. files a Form 144 notice for the proposed sale of 20,000 ordinary shares acquired upon exercise of employee stock options on 07/06/2026, with cash payment upon exercise. The filing also lists recent sales by the holder between 06/23/2026 and 07/02/2026, including multiple transactions totaling several blocks of ordinary shares.